Evidence map›Paper›PMID 29955172›Full record

ArticleEuropean journal of human genetics : EJHG2018

Primary brain calcification: an international study reporting novel variants and associated phenotypes.

Eliana Marisa Ramos, Miryam Carecchio, Roberta Lemos, Joana Ferreira, Andrea Legati, Renee Louise Sears, Sandy Chan Hsu, Celeste Panteghini, Luca Magistrelli, Ettore Salsano and 28 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Bilateral Cerebral Calcifications in Secondary Fahr's Syndrome.Case reports in neurological medicine · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The Genetics of Primary Familial Brain Calcification: A Literature Review.International journal of molecular sciences · 2023
    Review
  18. Brain Calcifications: Genetic, Molecular, and Clinical Aspects.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Eliana Marisa RamosDepartment of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Miryam CarecchioMolecular Neurogenetics Unit, Movement Disorders Section, IRCCS Foundation Carlo Besta Neurological Institute, Via L. Temolo n. 4, Milan, 20116, Italy.
Roberta LemosKeizo Asami Laboratory, Universidade Federal de Pernambuco, Recife, Brazil.
Joana FerreiraKeizo Asami Laboratory, Universidade Federal de Pernambuco, Recife, Brazil.
Andrea LegatiDepartment of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8178-6126
Renee Louise SearsDepartment of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Sandy Chan HsuDepartment of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Celeste PanteghiniMolecular Neurogenetics Unit, Movement Disorders Section, IRCCS Foundation Carlo Besta Neurological Institute, Via L. Temolo n. 4, Milan, 20116, Italy.
Luca MagistrelliDepartment of Neurology, University of Eastern Piedmont, C.so Mazzini 18, Novara, 28100, Italy.
Ettore SalsanoDepartment of Clinical Neurosciences, IRCCS Foundation Carlo Besta Neurological Institute, Via Celoria 11, Milan, 20131, Italy.
Silvia EspositoDepartment of Pediatric Neurology, IRCCS Foundation Carlo Besta Neurological Institute, Via Celoria 11, Milan, 20131, Italy.
Franco TaroniIRCCS Foundation Carlo Besta Neurological Institute, Via Amadeo 42, Milan, 20133, Italy.
Anne-Claire RichardNormandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and CNR-MAJ, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.
Christine TranchantService de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Mathieu AnheimService de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Xavier AyrignacDepartment of Neurology, Montpellier University Hospital, Montpellier, France.
Cyril GoizetCHU Bordeaux, Service de Génétique Médicale, 33000, Bordeaux, France.
Marie VidailhetDépartement de neurologie, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, UPMC Univ Paris 06, Inserm U1127, CNRS UMR 7225, ICM, F-75013, Sorbonne Universites, Paris, France.
David MalteteNormandie Univ, UNIROUEN, Inserm U1073, Rouen University Hospital, Department of Neurology, F 76000, Rouen, France.
David WallonNormandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.
Thierry FrebourgNormandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and CNR-MAJ, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.
Lylyan PimentelKeizo Asami Laboratory, Universidade Federal de Pernambuco, Recife, Brazil.
Daniel H GeschwindDepartment of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Olivier VanakkerCenter for Medical Genetics, Ghent University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium.
Douglas GalaskoVeterans Affairs Medical Center, San Diego and University of California, San Diego, USA.
Brent L FogelDepartments of Neurology and Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
A Micheil InnesDepartment of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada.ORCID http://orcid.org/0000-0001-9881-5467
Alison RossDepartment of Clinical Genetics, Ashgrove House, Foresterhill, Aberdeen, UK.
William B DobynsDepartments of Pediatrics and Neurology, University of Washington; and Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7681-2844
Diana AlcantaraGenome Damage & Stability Centre, University of Sussex, Brighton, UK.
Mark O'DriscollGenome Damage & Stability Centre, University of Sussex, Brighton, UK.
Didier HannequinNormandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology, Department of Genetics and CNR-MAJ, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.
Dominique CampionNormandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and CNR-MAJ, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.
French PFBC study group
João R OliveiraKeizo Asami Laboratory, Universidade Federal de Pernambuco, Recife, Brazil.
Barbara GaravagliaMolecular Neurogenetics Unit, Movement Disorders Section, IRCCS Foundation Carlo Besta Neurological Institute, Via L. Temolo n. 4, Milan, 20116, Italy.
Giovanni CoppolaDepartment of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. gcoppola@ucla.edu.ORCID http://orcid.org/0000-0003-2105-1061
Gaël NicolasNormandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and CNR-MAJ, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France. gaelnicolas@hotmail.com.ORCID http://orcid.org/0000-0001-9391-7800

Funding

Mosaic: post-zygotic mutations in vascular malformationsR01HL130996 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI BENNETT, JAMES T · 2016 to 2024
$7.5M
Integrative Center for Neurogenetics and Neurogenomics - OverallP30NS062691 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COPPOLA, GIOVANNI · 2009 to 2018
$7.4M
Rare and Novel Genetic Variation in the Pathogenesis of Cerebellar AtaxiaR01NS082094 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FOGEL, BRENT LINDEN · 2013 to 2017
$1.7M
THE GENETICS OF IDIOPATHIC BASAL GANGLIA CALCIFICATIONR01NS040752 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GESCHWIND, DANIEL H · 2001 to 2004
$1.3M
Cancer Research UK 15394Cancer Research UK C24110/A15394NHLBI NIH HHS R01 HL130996NINDS NIH HHS P30 NS062691NINDS NIH HHS R01 NS040752NINDS NIH HHS R01 NS082094
6 · The paper itself

Abstract

Primary familial brain calcification (PFBC) is a rare cerebral microvascular calcifying disorder with a wide spectrum of motor, cognitive, and neuropsychiatric symptoms. It is typically inherited as an autosomal-dominant trait with four causative genes identified so far: SLC20A2, PDGFRB, PDGFB, and XPR1. Our study aimed at screening the coding regions of these genes in a series of 177 unrelated probands that fulfilled the diagnostic criteria for primary brain calcification regardless of their family history. Sequence variants were classified as pathogenic, likely pathogenic, or of uncertain significance (VUS), based on the ACMG-AMP recommendations. We identified 45 probands (25.4%) carrying either pathogenic or likely pathogenic variants (n = 34, 19.2%) or VUS (n = 11, 6.2%). SLC20A2 provided the highest contribution (16.9%), followed by XPR1 and PDGFB (3.4% each), and PDGFRB (1.7%). A total of 81.5% of carriers were symptomatic and the most recurrent symptoms were parkinsonism, cognitive impairment, and psychiatric disturbances (52.3%, 40.9%, and 38.6% of symptomatic individuals, respectively), with a wide range of age at onset (from childhood to 81 years). While the pathogenic and likely pathogenic variants identified in this study can be used for genetic counseling, the VUS will require additional evidence, such as recurrence in unrelated patients, in order to be classified as pathogenic.

Indexed as

AdolescentAdultAgedAged, 80 and overBrain DiseasesCalcinosisChildCognitive DysfunctionFemaleGenetic VariationHeterozygoteHumansMaleMiddle AgedMutationPedigreePDGFRB protein, humanProto-Oncogene Proteins c-sisReceptor, Platelet-Derived Growth Factor betaReceptors, G-Protein-CoupledReceptors, VirusSLC20A2 protein, humanSodium-Phosphate Cotransporter Proteins, Type IIIXenotropic and Polytropic Retrovirus ReceptorXPR1 protein, human

Identifiers

PMID29955172
PMCPMC6138755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.